A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01678573
A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 169
- Registration Number
- NCT01677598
A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01674322
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
Phase 1
Completed
- Conditions
- Prostate Neoplasms
- Interventions
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT01664728
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 201
- Registration Number
- NCT01662310
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT01656330
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TMC278, Long acting (LA)
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2016-04-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT01656018
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT01655147
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 280
- Registration Number
- NCT01646021
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: Placebo + methotrexate (MTX) (Group 1)Drug: CNTO 1959 + MTX (Group 4)Drug: CNTO 1959 + MTX (Group 5)
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 274
- Registration Number
- NCT01645280
© Copyright 2025. All Rights Reserved by MedPath